KalVista Pharmaceuticals (KALV) Revenue (2014 - 2025)

KalVista Pharmaceuticals (KALV) reported Revenue of $50.0 million for Q3 2025, up 354.55% sequentially from $11.0 million in Q2 2025.

KalVista Pharmaceuticals (KALV) Revenue (2014 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 8 years of Revenue data on file, last reported at $50.0 million in Q3 2025.

For the quarter ending Q3 2025, Revenue changed N/A year-over-year to $50.0 million; the trailing twelve-month figure through Jul 2025 stood at $64.8 million (up 595.46% YoY), and the FY2025 full-year result was $11.0 million, down 78.0% from the prior year.
Revenue grew to $50.0 million in Q3 2025, from $11.0 million in the prior quarter.
In the past five years, Revenue ranged from a high of $50.0 million in Q3 2025 to a low of $11.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	KalVista Pharmaceuticals	1.36 Bn	1.36 Bn	49.41 Mn	50.00 Mn

Download Data